Mirati Therapeutics, Inc. received FDA approval for its oral KRAS G12C inhibitor KRAZATI (adagrasib), a move that solidifies its position in a highly competitive oncology landscape but faces an uphill battle against peers like Amgen and Loxo in the KRAS inhibitor market. The launch of adagrasib is expected to drive near-term revenue growth but faces scrutiny regarding evolving accessibility and competition pricing as the company navigates a strategic pivot away from in-house manufacturing.